Zaltrap

Active Ingredient(s): Ziv aflibercept
FDA Approved: * August 3, 2012
Pharm Company: * SANOFI AVENTIS US
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zaltrap Overview

Aflibercept is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap. As the active ingredient of Zaltrap, the substance is called ziv-aflibercept in the United States. It is an inhibitor of vascular endothelial growth factor (VEGF).[1][2] Aflibercept is being co-developed for cancer treat...

Read more Zaltrap Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Aflibercept

Recent Zaltrap Forums:

Possible Dosages for this and Related Drugs:

NDC Database Records for Zaltrap: (2 results)

Sorted by National Drug Code

• 0024-5840 Zaltrap 100 mg/4ml Intravenous Solution, Concentrate by Sanofi-aventis U.S. LLC
• 0024-5841 Zaltrap 200 mg/8ml Intravenous Solution, Concentrate by Sanofi-aventis U.S. LLC

Other drugs which contain Ziv aflibercept or a similar ingredient: (1 result)

• ZIV AFLIBERCEPT

Related Zaltrap Topics: